2020 Feb 22;192:112163. doi: 10.1016/j.ejmech.2020.112163.Author information
Abstract
Herein, 11 general types of natural cannabinoids from Cannabis sativa as well as 50 (-)-CBD analogues with therapeutic potential were described. The underlying molecular mechanisms of CBD as a therapeutic candidate for epilepsy and neurodegenerative diseases were comprehensively clarified. CBD indirectly acts as an endogenous cannabinoid receptor agonist to exert its neuroprotective effects. CBD also promotes neuroprotection through different signal transduction pathways mediated indirectly by cannabinoid receptors. Furthermore, CBD prevents the glycogen synthase kinase 3β (GSK-3β) hyperphosphorylation caused by Aβ and may be developed as a new therapeutic candidate for Alzheimer’s disease.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
KEYWORDS: Alzheimer’s disease (AD), Cannabidiol (CBD), Cannabinoids, Cannabis, Epilepsy, Neurodegenerative disease
- PMID: 32109623
- DOI: 10.1016/j.ejmech.2020.112163
Conflict of interest statement
Declaration of competing interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
